Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04768309
Other study ID # 69HCL20_1078
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date June 4, 2021
Est. completion date July 13, 2021

Study information

Verified date September 2023
Source Hospices Civils de Lyon
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Chronic renal failure (CKD) affects 3 million people in France and is characterized by the accumulation of uremic toxins (UTs) such as p-cresyl sulfate (PCS) and indoxyl sulfate (IS) which participate in cardiovascular complications and disturbance of the carbohydrate metabolism associated with CKD. These UTs are not eliminated by dialysis due to their high affinity for albumin and alternative strategies to dialysis must be developed to decrease the production of TUs in patients not yet in dialysis. The dysregulation of the intestinal microbiota observed during CKD increases the generation of UTs in the intestine, by the transformation of amino acids derived from proteins (such as tyrosine and tryptophan transformed respectively into PCS and, IS). Thus, modulation of the intestinal microbiota seems to be an attractive target for reducing the production of UTs and the comorbidities associated with CKD. Some studies have demonstrated the potential interest of probiotics in lowering the plasma concentration of UTs, but the effects remain unclear. In order to test the interest of probiotics during CKD, the investigators have, in collaboration with the Nestlé laboratory and the ProDigest platform, the possibility of testing probiotics using a human intestine simulator before the investigation of experimental and human models. For this the investigators would need a collection of fresh stools. The fresh stools will be instilled in artificial intestine to test the efficacy of selected probiotics on UTs production.


Recruitment information / eligibility

Status Completed
Enrollment 20
Est. completion date July 13, 2021
Est. primary completion date July 13, 2021
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 80 Years
Eligibility Inclusion Criteria: - Age between 18 and 80 years old - Non diabetic (fasting blood glucose <1.26 g / L, or lack of insulin or oral antidiabetic treatment) - BMI between 18 and 30 kg / m² - Patient with CKD stage 4-5 ( eDFG < 30 ml/min/1.73m2 CKD-EPI) - Not dialyzed - No history of kidney transplant - Patient followed in the nephrology department of Pr FOUQUE at the Lyon Sud hospital center Exclusion Criteria: - Active inflammatory, infectious, cardiovascular or neoplastic disease - Colectomy, resection of the small intestine or cholecystectomy - Patient having received antibiotics, prebiotics, probiotics in the last 3 months. - Patient using laxatives (more than 2 doses per day for the last 3 months) - Known renal pathology or known urologic malformation (healthy volunteer only)

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Ex vivo exploration of the effect of a probiotic over precursor indole production
Fresh feces in chronic kidney patients and healthy volunteers will be collected. The feces will be instilled in artificial intestine with and without selected probiotics and production of uremic toxins will be measured.

Locations

Country Name City State
France Lyon Sud University Hospital Pierre-Bénite Rhône

Sponsors (1)

Lead Sponsor Collaborator
Hospices Civils de Lyon

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Production of precursor of one of major uremic toxins: indole The main endpoint is the concentration of the precursor of indoxyl sulfate (indole) in the lumen of the artificial intestine with a microbiota of a patient with CKD compared to the concentration of indol in the lumen of artificial intestine with a microbiota from a patient with CKD and supplemented with a probiotic (supplied by Nestlé) Indoles production will be measured 48 hours after instillation of fresh feces in the artificial intestine
Secondary Uremic toxins production Concentration of various uremic toxins in a human intestine simulator (p-cresyl sulfate, p-cresol, indole-3-acetic acid, etc.). 48 hours after instillation of fresh feces in the human intestine simulator
Secondary Production of short-chain fatty acids (SCFA) Concentration of short-chain fatty acids (SCFA) (acetate, propionate, butyrate, isobutyrate, isovalerate and isocaproate) human intestine simulator 48 hours after instillation of fresh feces in the human intestine simulator
Secondary Intestinal permeability in a human intestine simulator It will be measured by the electrical transepithelial resistance of the intestinal cells. 48 hours after instillation of fresh feces in the human intestine simulator
Secondary Biochemical parameters Concentration of ammonium and lactate in a human intestine simulator. 48 hours after instillation of fresh feces in the human intestine simulator
Secondary Biochemical parameters pH levels of the human intestine simulator. 48 hours after instillation of fresh feces in the human intestine simulator
Secondary Biochemical parameters Volume of gas production in a human intestine simulator. 48 hours after instillation of fresh feces in the human intestine simulator
Secondary Intestinal microbiota composition Study of the composition of the intestinal microbiota by 16s analysis 48 hours after instillation of fresh feces in the human intestine simulator
See also
  Status Clinical Trial Phase
Not yet recruiting NCT03277911 - Thyroid Dysfunction and Dyslipidemia in Patients With Chronic Kidney Diseases N/A
Active, not recruiting NCT04008810 - Serum Neutrophil Gelatinase-associated Lipocalins (NGAL) and Chronic Kidney Disease
Completed NCT05144971 - StatStrip A Glucose/Creatinine Meter System Lay User Study Evaluation
Active, not recruiting NCT05356325 - FGF23 and Cardiovascular Damage in Anemia With an Without Chronic Kidney Disease.
Not yet recruiting NCT04491669 - Screening of Gastrointestinal Tract Bleeding Causes Among Chronic Renal Failure Patients
Completed NCT04709120 - Analysis of Health Status of Сomorbid Adult COVID-19 Patients Hospitalised in Second Wave of SARS-CoV-2 Infection
Terminated NCT03277183 - Frequent, Low-Dose Erythropoietin A Mechanistic Approach to Mitigate Adverse Cardiovascular Effects of Erythropoietin Phase 4
Enrolling by invitation NCT04491227 - Global Assessment of Acute and Chronic Kidney Disease Incidence and Outcomes in Patients With COVID-19 Infection
Recruiting NCT06279429 - Sucrosomial Iron on Insomnia in Non-dialysis Chronic Kidney Disease Patients With Iron Deficiency Anemia N/A
Recruiting NCT03501745 - Smart-CKD/BP Study N/A
Recruiting NCT04708743 - The Tongue Features Associated With Chronic Kidney Disease
Recruiting NCT06416761 - Genetics in the Progression of Nephropathies
Completed NCT04119570 - CKD Report Card Pilot Trial N/A
Completed NCT06374043 - Decentralized N=1 Study: A Feasible Approach to Evaluate Individual Therapy Response to Dapagliflozin. Phase 4
Not yet recruiting NCT06094920 - Treatment Optimization for Patients With Type 2 Diabetes Using Empagliflozin and Finerenone in a Remote Clinical Trial Phase 4
Recruiting NCT04819217 - Study of Oral Uremic Toxin Absorbent and Probiotics to Retard the Progression of Chronic Kidney Disease N/A
Completed NCT05970094 - Reduction of Metabolic Acidosis in Patients With Chronic Kidney Disease in Stage 4 and 5 N/A
Withdrawn NCT04782297 - Long Term Hemodialysis Catheters (LTHD) Post Market Clinical Follow up (PMCF)
Recruiting NCT05784389 - Reduction of Metabolic Acidosis in Patients With Chronic Kidney Disease in Stage 4 and 5 N/A
Recruiting NCT04630132 - Renal Ageing-sarcopenia Network